Market Research Reports

3,400+
Reports
16
Verticals
10yr
Forecasts
Filter:AllPharmaceuticalsMedical DevicesBiotechnologyHealthcare ITConsumer GoodsF&BChemicalsTechnologyPackagingSemiconductorAgricultureVeterinary

Preclinical Oncology Models Market Size, Share & Trends Analysis Report By Product (Neuroblastoma, Prostate Cancer, Pancreatic Cancer, Breast Cancer, Colorectal Cancer, Bladder Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Skin Cancer, Others), By Application, By Model Host Species, By Region, And Segment Forecasts, 2025-2034

Global Preclinical Oncology Models Market is valued at USD 1335.7 Million in 2024 and is predicted to reach USD 3733.0 Million by 2034, at a 10.9% CAGR during the forecast period 2025-2034. The rise of immuno-oncology therapy such as T cell therapy, bispecific antibodies, immune checkpoint modulators, and personalized cancer vaccines compels the need for unique preclinical and translational service solution. Recently advances in Immuno-oncolog...

ID: 1093 180 Pages November 2025

HIV Drugs Market Size, Share, Trend, Scope Report 2026 to 2035

What is HIV Drugs Market Size? Global HIV Drugs Market Size is valued at USD 40.21 Billion in 2025 and is predicted to reach USD 64.12 Billion by the year 2035 at a 5.0% CAGR during the forecast period for 2026 to 2035. HIV Drugs Market Size, Share & Trends Analysis Report By Drug Type (Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integras...

ID: 1092 180 Pages January 2026

Gene Therapies For Rare Diseases Market Size, Share & Trends Analysis Report By Product (Zolgensma, Invossa K, Strimvelis, Neovasculgen, Glybera, Luxturna, Zynteglo, and Others), By Disease Type, Region And Segment Forecasts, 2023-2031.

The Gene Therapies For Rare Diseases Market is expected to grow at an 20.0 % CAGR during the forecast period for 2023-2031. Gene Therapy is playing a major role in rare disease management. Gene therapy in rare diseases is a specialized and targeted treatment that acts via the insertion of corrected genes into cells of an individual. Around 80 percent of rare diseases are accounted with genetic etiology. Gene therapy is considered as proven wit...

ID: 1091 180 Pages November 2024

CBD Pet Market Size, Scope, Forecast Report 2026 to 2035

What is CBD Pet Market Size? CBD Pet Market Size is valued at USD 347.53 million in 2025 and is predicted to reach USD 2,868.57 million by the year 2035 at a 24.3% CAGR during the forecast period for 2026 to 2035. CBD Pet Market Size, Share & Trends Analysis Report, By Product (Therapeutic Grade (Pet Supplements, Pet CBD Oil), Food grade (Treats, Chews)), By Application (Joint Pain, Anxiety/Stress, Epilepsy, General Health/Wellness), End Us...

ID: 1089 180 Pages January 2026

CAR-T Cell Therapy for Multiple Myeloma Market Size, Share and Growth Analysis 2025 to 2034

What is CAR-T Cell Therapy for Multiple Myeloma Market Size? Global CAR-T Cell Therapy for Multiple Myeloma Market Size is valued at USD 2.32 Billion in 2025 and is predicted to reach USD 9.28 Billion by the year 2035 at an 15.0% CAGR during the forecast period for 2026 to 2035. CAR-T Cell Therapy for Multiple Myeloma Market Size, Share & Trends Analysis Report By Therapy Type (Bb2121, JNJ-68284528 (LCAR-B38M),...

ID: 1088 180 Pages March 2026

Oncolytic Virus Therapy Market Size, Revenue, Trend Report 2026 to 2035

What is Oncolytic Virus Therapy Market Size? Gloabal Oncolytic Virus Therapy Market Size is valued at USD 17.35 Million in 2025 and is predicted to reach USD 157.20 Million by the year 2035 at a 25.6% CAGR during the forecast period for 2026 to 2035.  Oncolytic Virus Therapy Market Size, Share & Trends Analysis Report By Product (Herpes Simplex Virus (HSV), Adenoviruses, Vaccinia Virus, Vesicular Stom...

ID: 1087 180 Pages February 2026

Capsule Endoscopy Market Current Trends Analysis 2026 to 2035

What is Capsule Endoscopy Market Size? Global Capsule Endoscopy Market Size is valued at USD 482.98 Million in 2025 and is predicted to reach USD 1049.93 Million by the year 2035 at a 8.2% CAGR during the forecast period for 2026 to 2035 Capsule Endoscopy Market Size, Share & Trends Analysis Report By Brand (CapsoCam Plus, Capso Retrieve, CapsoAccess, CapsoView, Check-cap, OMOM, MicroCam Regular, PillCam, EndoCapsule, Sayaka, Othe...

ID: 1086 180 Pages March 2026

Alternative Proteins Market Current Trends Analysis 2026 to 2035

What is Alternative Proteins Market Size? Alternative Proteins Market Size is valued at USD 18.01 Bn in 2025 and is predicted to reach USD 61.69 Bn by the year 2035 at a 13.70% CAGR during the forecast period for 2026 to 2035. Alternative Proteins Market Size, Share & Trends Analysis Report, By Product (Plant Protein, Microbe-based Protein, Insect Protein), By Application (Food & Beverages, Clinical Nutrition, Animal Feed, Oth...

ID: 1085 180 Pages February 2026

Allogeneic Cell Therapy Market Size, Share and Key Players Analysis 2026 to 2035

What is Allogeneic Cell Therapy Market Size? Allogeneic Cell Therapy Market Size is valued at 1.33 Million in 2025 and is predicted to reach 4.49 Billion by the year 2035 at a 13.30% CAGR during the forecast period for 2026 to 2035. Allogeneic Cell Therapy Market Size, Share & Trends Analysis Report By Type of Cell Therapy (Virus-Specific T-Cell, Stem Cell, Regulatory T-Cell), By Source of Cell, By Target Indication, By Therapeuti...

ID: 1084 180 Pages February 2026

Immuno-Oncology Cell Therapy Market Size, Share & Trends Analysis Report By Therapy Type (CAR-T Cells, NK & NKT Cells, TAA/TSA targeted T Cell, TCR T Cell, and Other Cell Therapies), By Cell Source, By Indication Type, By Region, And Segment Forecasts, 2025-2034

Global Immuno-Oncology Cell Therapy Market Size is valued at USD 11.9 Billion in 2024 and is predicted to reach USD 95.3 Billion by the year 2034 at a 23.2% CAGR during the forecast period for 2025-2034. Immuno-oncology cell therapies are a remarkably promising treatment for a different types of cancer patients. The approval of CAR-T cell therapy products represents one of the most significant breakthroughs in cancer since the introduction of ...

ID: 1083 180 Pages November 2025

AI-Based Clinical Trial Solution Providers Market Size, Share, Scope Report 2026 to 2035

What is AI-Based Clinical Trial Solution Providers Market Size? Global AI-Based Clinical Trial Solution Providers Market Size is valued at USD 2.65 Billion in 2025 and is predicted to reach USD 21.03 Billion by the year 2035 at a 23.7% CAGR during the forecast period for 2026 to 2035. AI-Based Clinical Trial Solution Providers Market Size, Share & Trends Analysis Report By Target Therapeutics (Cardiovascular Disorders, CNS Disorde...

ID: 1082 180 Pages January 2026

Rituximab Biosimilar Market Size, Share & Trends Analysis Report By Brand, By Application, By Route of Administration, By Molecule Type, By Distribution Channel Region And Segment Forecasts, 2025-2034

Rituximab Biosimilar Market is expected to grow at a 12.3% CAGR during the forecast period for 2025-2034. Rituximab is a chimeric anti-CD20 antibody that binds to the CD20 antigen present on the standard and malignant B cells surface. It is indicated for the treatment of blood cancer (CD20-positive) such as chronic lymphocytic leukemia and non-Hodgkin’s lymphoma, as well as an autoimmune disorder such as Rheumatoid arthritis. Rituximab i...

ID: 1081 180 Pages June 2025

Trastuzumab Biosimilar Market Size, Share, Trend Report 2026 to 2035

What is Trastuzumab Biosimilar Market Size? Trastuzumab Biosimilar Market is expected to grow at a 25.0 % CAGR during the forecast period for 2026 to 2035. Trastuzumab Biosimilar Market Size, Share & Trends Analysis Report By Product (Ogivri, Herzuma, Ontruzant, Trazimera, Other Pipeline Products), By Indication, By Route of Administration, By Molecule Type, Region And Segment Forecasts, 2026 to 2035. Trastuzumab Biosimilar Marke...

ID: 1080 180 Pages January 2026

Anti-Nerve Growth Factor Market Outlook, Clinical Trial/Pipeline Analysis, Competitive Landscape, and Market Forecast Report – 2023 To 2031

The nerve growth factor is a tumor tissue produced growth factor that promotes the growth and differentiation of sympathetic and sensory ganglia. It is the first growth factor to be identified. An elevated level of nerve growth factor leads to inflammation and peripheral nerve injury. The nerve growth factor is secreted in the body following stimulus (eg, chemical, thermal, or mechanical). Clinically, an elevated level of nerve growth factor in t...

ID: 1079 180 Pages November 2024

Cancer Biosimilars Market Size, Share & Trends Analysis Report By Type (Lung Cancer, Breast cancer, Ovarian cancer, Prostate cancer, Lymphoma, Others), By Distribution Channel, By Drug Class, By Route of Administration, Region And Segment Forecasts, 2023-2031

The Cancer Biosimilars Market is expected to grow at a 20.0 % CAGR during the forecast period for 2023-2031.   Biosimilar is defined as a type of biological product that is approved by respective regulatory bodies because of its clinical similarity to already approved biological products. This is relatively cheaper than biologics. The abnormal growth of call is called cancer. Cancer is the second leading cause of death across the globe. Ma...

ID: 1078 180 Pages June 2025

Abdominal Aorta Stent Grafts Market Size, Share & Trends Analysis Report By Product Type (Polymer, Metal), By End-Users (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), Region, And Segment Forecasts, 2025-2034

Global Abdominal Aorta Stent Grafts Market is expected to grow at a 4.9% CAGR during the forecast period for 2025-2034. The Aortic abdominal stent graft is used for abdominal aneurysm endovascular repair. Endovascular aneurysm repair (EVAR), is a new treatment option for abdominal aortic aneurysm in which a graft is inserted into the aorta to strengthen it. This surgery doesn’t need surgically opening the chest or abdomen and is done using...

ID: 1077 180 Pages May 2025

Filgrastim Biosimilars Market Size, Share, Trend Report 2026 to 2035

What is Filgrastim Biosimilars Market Size? Global Filgrastim Biosimilars Market Size was valued at USD 1.22 Bn in 2025 and is predicted to reach USD 3.93 Bn by 2035 at a 12.5% CAGR during the forecast period for 2026 to 2035. Filgrastim Biosimilars Market Size, Share & Trends Analysis Report By Application (Febrile Neutropenia, Genital Neutropenia, Idiopathic Neutropenia, and Others), By Distribution Channel (Online Pha...

ID: 1076 180 Pages May 2026

Global Cancer Immunomodulators Pipeline Market

Prevention of progression and proliferation of infectious diseases in the body has always been the point of discussion, which has developed a throng of techniques to alter these effects of the immune system. Immunotherapy is a treatment that uses particular parts of a person’s immune organism to fight against cancer. The immune system is a collection of special cells, organs and substances which protect us from diseases and infections. Immu...

ID: 1074 180 Pages October 2024

Bevacizumab Biosimilar Market Size, Share & Trends Analysis Report By Product (Abevmy, Alymsys, Avastin, Avzivi, Avzivi tnjn, Aybintio, Bambevi, Equidacent, Jobevne, Lextemy, Lytenava, Mvasi, Onbevzi, Oyavas, Vegzelma, Zirabev, and others (including products approved in developing countries and pipeline products), By Application, By Distribution Channel, Region And Segment Forecasts, 2025-2034

Global Bevacizumab Biosimilar Market is expected to grow at an 9.0% CAGR during the forecast period for 2025-2034. Bevacizumab is a recombinant humanized monoclonal antibody that neutralizes vascular endothelial growth factor A (VEGF-A) biologic activity (an essential endothelial cell mitogen and survival factor). It is the first anti-angiogenic therapy approved for the treatment of human cancer. The drug was developed by F. Hoffmann-La Roche AG...

ID: 1073 180 Pages October 2025

TNF Biosimilars Market Size, Share & Trends Analysis Report By Drug (Adalimumab Biosimilar, Infliximab Biosimilar, Certolizumab Biosimilar, Etanercept Biosimilar, and Golimumab Biosimilar), By Distribution Channel (Online Pharmacy, Hospital Pharmacy, Retail Pharmacy), Region And Segment Forecasts, 2025-2034

TNF Biosimilars Market is expected to grow at a 16.5% CAGR during the forecast period for 2025-2034.  Tumor necrosis factors are a group of cytokines that are secreted by macrophages and may induce cell death of certain tumor cell lines, which leads to inflammation. TNF inhibitors are the drug that stops inflammation. They are mainly indicated for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, anklyosing Spo...

ID: 1072 180 Pages June 2025